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Response to Letter to the Editor: ‘Re: Endograft Limb
Occlusion in EVAR: Iliac Tortuosity Quantiﬁed by Three
Different Indices on the Basis of Pre-operative CTA’
We thank the group for their insightful comments and the
opportunity to clarify a number of points from our work on
endograft limb occlusion.
In our series to determine a cut-off value of common iliac
artery tortuosity index (CAI) for high-risk patients, we con-
structed a receiver operating characteristic (ROC) curve. The
area under curve was 0.72 (95% CI 0.55e0.88) with a best
cut-off value of 1.26. With CAI  1.26, the positive pre-
dictive value was 67% and the negative predictive value was
65%. The sensitivity and speciﬁcity were 59% and 85%,
respectively. The relative risk for limb occlusion was 2.8.
Our article is a cohort study, so we do acknowledge the
limitation of the chosen control group. Four patients in the
control group had double iliac sign (DIS), and two of these
had primary adjunctive stenting performed. In our series we
simply state the observation that two other patients with
DIS had their z-stent part of the graft limbs placed directly
within the most tortuous part of the vessel, therefore
having the part of the graft limb with the most radial force
where it was needed. We acknowledge this may simply be
pure speculation.
During the extended decade period 2000e2010, we used
only the Zenith ﬂex (Cook Inc, Bloomington, IN, USA) limbs.
The incidence of limb occlusions was equally distributed in
the time period.
We hope that other centres will review and publish their
survival results to provide further information, and we hope
this will provide a more robust answer to some of the
questions that have been raised.
M. Taudorf, T.V. Schroeder, L. Lönn, On behalf of the co-
authors
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Re. ‘Beneﬁts of Remote Ischemic Preconditioning
in Vascular Surgery’
We read with interest the review article of Twine et al.1 In
recent years several articles have addressed this topic and
reported various results with regard to the extent of organ
protection. In our opinion, it is to be expected that the
clinical application of this technique will encounter similar
drawbacks as we have witnessed with the concept of
ischemic and pharmacological preconditioning. Indeed,
despite the promising data from experimental studies, the
implementation of preconditioning strategies in clinical
practice was disappointing.
This apparent discrepancy between experimental and
clinical data is multifactorial but central in this is the fact that
a cardiac or vascular patient with his associated pathology
can by no means be compared to an experimentaldmostly
healthydanimal model. Associated pathology such as for
instance diabetes and concurrent medication have been
shown to interfere with the mechanisms of preconditioning.
As such, the beneﬁcial effects of these strategies may very
well be blocked by these factors.
Another key element that is frequently overlooked is the
concurrent inﬂuence of anesthetic agents. Volatile anes-
thetics have a pharmacological preconditioning effect, and,
speciﬁcally in coronary surgery, it has been shown that the
use of such agents was associated with less postoperative
myocardial damage and a better preservation of myocardial
function.2,3 Interestingly, when a remote ischemic pre-
conditioning protocol was applied on top of a volatile
anesthetic regimen, no additional protection was
observed.4 We therefore suggest that future studies and
reports take this variable into account. It is very well
possible that the absence of effect in certain remote
ischemic preconditioning protocols may be related to the
fact that the strategy was applied on top of a volatile
anesthetic based anesthesia.
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Response to ‘Re. Beneﬁts of Remote Ischemic
Preconditioning in Vascular Surgery’
The authors make a good point: discrepancy between ani-
mal and clinical data is multifactorial, and the factors they
cite are likely to be an inﬂuence.
Themost recent, properly powered randomised controlled
trial (RCT) of remote ischaemic preconditioning (RIPC) in
cardiac surgery avoided the use of volatile anaesthetic agents
to avoid pharmacological preconditioning.1 This trial showed
no difference between the RIPC and no RIPC groups.
Conversely, the large RIPCON (Remote Ischemic Pre-
Conditioning) trial of RIPC in cardiac surgery is currently
recruiting using volatile agents to avoid remifentanyl,2 which
is also associated with pharmacological preconditioning.3
This highlights one of the problems with medications and
RIPC: it might be impossible to avoid those that effect RIPC
completely, but trials can adjust for the least powerful.
Additionally, patients might fare worse with the pre-
conditioning effect of RIPC than they would have done with
the preconditioning effect of the medication being withheld.
Another problem is that the mechanisms of interference are
still poorly understood, and it is likely that additional,
commonly prescribed medicines have an effect on RIPC.3,4
Other factors such as diabetes are common in vascular pa-
tients should be corrected for if trials are properly powered.
Protocols for other trials currently or about to recruit are
heterogeneous in their approach to correcting for these
factors. To date, 102 trials of remote ischaemic pre-
conditioning are registered on ClinicalTrials.gov. It is
imperative that trialists recognise and attempt to correct for
these factors as early as possible. Without this, we risk
publishing large, ﬂawed trials that essentially destroy all
interest in RIPC without a rigorous method.
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Thrombolysis in Carotid-Related Stroke Patients: What
About Plaque Hemorrhage and Disruption?
The routine practice of thrombolysis in ischemic stroke pa-
tients is derived from well-conducted, randomized controlled
trials (RCTs),1 which are the foundation of evidence-based
medicine (EBM). Those studies have proved themselves
extremely useful for stroke patients, helping somanypeople to
have better outcomes after their strokes. Currently, intrave-
nous thrombolytic therapy is recommended within 4.5 hours
of the onset of symptoms in patients with acute ischemic
stroke, once intracranial bleeding has been excluded by
computed tomography.2,3 The exact identiﬁcation of the site
of occlusion causing the ischemia or, more in general, of the
exact cause of stroke, is not considered mandatory before
starting ﬁbrinolytic therapy, as none of the RCTs studying the
effect of rt-PA in ischemic stroke patients was designed to
address the differential effects on different types or causes of
ischemic strokes by using vascular imaging.4,5 Hence, a carotid
axis scan is not routinely performed until the rt-PA adminis-
tration has been completed. Unfortunately, it is likely that not
all the patients receiving intravenous systemic rt-PA will gain
the greatest efﬁcacy and beneﬁt from ﬁbrinolytic therapy, and
this is probably related to the lack of a careful diagnosis of the
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